Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
Summary by Financial Post
5 Articles
5 Articles
All
Left
3
Center
Right
1

+3 Reposted by 3 other sources
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
SHANGHAI, April 25, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application…
·Hamilton, Canada
Read Full ArticleCoverage Details
Total News Sources5
Leaning Left3Leaning Right1Center0Last UpdatedBias Distribution75% Left
Bias Distribution
- 75% of the sources lean Left
75% Left
L 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage